Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of Disaggregated Research and Development Expenses and Segment Net Loss

In addition to the significant expense categories included on the Company's consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):


	For the three months ended June 30,						For the six months ended June 30,
	2025			2024			2025			2024
Operating expenses:
Research and development operating costs and expenses excluding non-cash stock-based compensation:
Primary program research and development expenses (a)	$	16,708		$	13,579		$	31,447		$	26,043
Payroll and benefits		3,210			2,946			6,098			5,603
Occupancy and other overhead and operating costs		448			492			1,074			875
Total other research and development expenses		3,658			3,438			7,172			6,478
Research and development operating costs and expenses excluding non-cash stock-based compensation:		20,366			17,017			38,619			32,521
General and administrative expense excluding non-cash stock-based compensation		8,371			3,944			15,551			8,626
Other segment income (expense), net (b)		1,664			1,282			2,870			1,442
Segment net loss	$	(30,401	)	$	(22,243	)	$	(57,040	)	$	(42,589	)

Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.

Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt and tax credit income.